Literature DB >> 12403821

Synthetic small inhibiting RNAs: efficient tools to inactivate oncogenic mutations and restore p53 pathways.

Luis Alfonso Martinez1, Irina Naguibneva, Heike Lehrmann, Arlette Vervisch, Thierry Tchénio, Guillermina Lozano, Annick Harel-Bellan.   

Abstract

Single base pair mutations that alter the function of tumor suppressor genes and oncogenes occur frequently during oncogenesis. The guardian of the genome, p53, is inactivated by point mutation in more than 50% of human cancers. Synthetic small inhibiting RNAs (siRNAs) can suppress gene expression in mammalian cells, although their degree of selectivity might be compromised by an amplification mechanism. Here, we demonstrate that a single base difference in siRNAs discriminates between mutant and WT p53 in cells expressing both forms, resulting in the restoration of WT protein function. Therefore, siRNAs may be used to suppress expression of point-mutated genes and provide the basis for selective and personalized antitumor therapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12403821      PMCID: PMC137507          DOI: 10.1073/pnas.222406899

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  39 in total

1.  siRNA-directed inhibition of HIV-1 infection.

Authors:  Carl D Novina; Michael F Murray; Derek M Dykxhoorn; Paul J Beresford; Jonathan Riess; Sang-Kyung Lee; Ronald G Collman; Judy Lieberman; Premlata Shankar; Phillip A Sharp
Journal:  Nat Med       Date:  2002-06-03       Impact factor: 53.440

2.  Oncogenic forms of p53 inhibit p53-regulated gene expression.

Authors:  S E Kern; J A Pietenpol; S Thiagalingam; A Seymour; K W Kinzler; B Vogelstein
Journal:  Science       Date:  1992-05-08       Impact factor: 47.728

3.  A system for stable expression of short interfering RNAs in mammalian cells.

Authors:  Thijn R Brummelkamp; René Bernards; Reuven Agami
Journal:  Science       Date:  2002-03-21       Impact factor: 47.728

Review 4.  Li-Fraumeni syndrome.

Authors:  J M Birch
Journal:  Eur J Cancer       Date:  1994       Impact factor: 9.162

5.  WAF1, a potential mediator of p53 tumor suppression.

Authors:  W S el-Deiry; T Tokino; V E Velculescu; D B Levy; R Parsons; J M Trent; D Lin; W E Mercer; K W Kinzler; B Vogelstein
Journal:  Cell       Date:  1993-11-19       Impact factor: 41.582

6.  Spontaneous abnormalities in normal fibroblasts from patients with Li-Fraumeni cancer syndrome: aneuploidy and immortalization.

Authors:  F Z Bischoff; S O Yim; S Pathak; G Grant; M J Siciliano; B C Giovanella; L C Strong; M A Tainsky
Journal:  Cancer Res       Date:  1990-12-15       Impact factor: 12.701

7.  Gain of function mutations in p53.

Authors:  D Dittmer; S Pati; G Zambetti; S Chu; A K Teresky; M Moore; C Finlay; A J Levine
Journal:  Nat Genet       Date:  1993-05       Impact factor: 38.330

8.  p21 is necessary for the p53-mediated G1 arrest in human cancer cells.

Authors:  T Waldman; K W Kinzler; B Vogelstein
Journal:  Cancer Res       Date:  1995-11-15       Impact factor: 12.701

9.  Cyclin E restores p53 activity in contact-inhibited cells.

Authors:  A Deffie; M Hao; R Montes de Oca Luna; D L Hulboy; G Lozano
Journal:  Mol Cell Biol       Date:  1995-07       Impact factor: 4.272

10.  A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice.

Authors:  M Harvey; H Vogel; D Morris; A Bradley; A Bernstein; L A Donehower
Journal:  Nat Genet       Date:  1995-03       Impact factor: 38.330

View more
  54 in total

1.  A biochemical framework for RNA silencing in plants.

Authors:  Guiliang Tang; Brenda J Reinhart; David P Bartel; Phillip D Zamore
Journal:  Genes Dev       Date:  2003-01-01       Impact factor: 11.361

Review 2.  Pharmaceutical prospects for RNA interference.

Authors:  Raymond M Schiffelers; Martin C Woodle; Puthupparampil Scaria
Journal:  Pharm Res       Date:  2004-01       Impact factor: 4.200

3.  shRNA expression constructs designed directly from siRNA oligonucleotide sequences.

Authors:  Tuva Barøy; Kirsten Sørensen; Mona Mari Lindeberg; Eirik Frengen
Journal:  Mol Biotechnol       Date:  2010-06       Impact factor: 2.695

Review 4.  RNA interference: ready to silence cancer?

Authors:  Simone Mocellin; Rodolfo Costa; Donato Nitti
Journal:  J Mol Med (Berl)       Date:  2005-11-09       Impact factor: 4.599

Review 5.  Silence of the transcripts: RNA interference in medicine.

Authors:  Sailen Barik
Journal:  J Mol Med (Berl)       Date:  2005-07-19       Impact factor: 4.599

Review 6.  The canonical Wnt signalling pathway and its APC partner in colon cancer development.

Authors:  Jean Schneikert; Jürgen Behrens
Journal:  Gut       Date:  2006-07-13       Impact factor: 23.059

7.  Strand-specific 5'-O-methylation of siRNA duplexes controls guide strand selection and targeting specificity.

Authors:  Po Yu Chen; Lasse Weinmann; Dimos Gaidatzis; Yi Pei; Mihaela Zavolan; Thomas Tuschl; Gunter Meister
Journal:  RNA       Date:  2007-12-19       Impact factor: 4.942

Review 8.  Tumor-targeted delivery of siRNA by non-viral vector: safe and effective cancer therapy.

Authors:  Yunching Chen; Leaf Huang
Journal:  Expert Opin Drug Deliv       Date:  2008-12       Impact factor: 6.648

9.  Induction of alternative lengthening of telomeres-associated PML bodies by p53/p21 requires HP1 proteins.

Authors:  Wei-Qin Jiang; Ze-Huai Zhong; Akira Nguyen; Jeremy D Henson; Christian D Toouli; Antony W Braithwaite; Roger R Reddel
Journal:  J Cell Biol       Date:  2009-05-25       Impact factor: 10.539

10.  Selective RNAi-mediated inhibition of mutated c-kit.

Authors:  Irene Ruano; Marta Izquierdo
Journal:  J RNAi Gene Silencing       Date:  2009-02-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.